Loading…
Rallybio Corp Is A Clinical-Stage Biotechnology Company Comprised Of Experienced Biopharma Industry Leaders With Extensive Research, Development, And Rare Disease Expertise With A Mission To Develop And Commercialize Life-Transforming Therapies For Patients With Severe And Rare Diseases. The Company'S Program, Rlyb116, Is A Differentiated Complement Component 5 (C5) Inhibitor With The Potential To Treat Diseases Of Complement Dysregulation. The Company Manages Its Operations As A Single Segment For The Purposes Of Allocating Resources, Assessing Performance, And Making Operating Decisions. Rallybio'S Pipeline Also Includes Rlyb332, A Preclinical Long-Acting Matriptase-2 Antibody For The Treatment Of Diseases Of Iron Overload.